文献速递胸部技术与安全PET

椎体3'-脱氧-3'-18F-氟胸苷摄取预测肺癌患者全身化疗后的血液学毒性

The vertebral 3'-deoxy-3'-18F-fluorothymidine uptake predicts the hematological toxicity after systemic chemotherapy in patients with lung cancer.
PubMed 文献 · Eur Radiol · 2019-04-10

这项回顾性研究纳入50例原发性肺癌患者,在铂类双药化疗前进行18F-FLT PET扫描,评估椎体标准化摄取值、总椎体增殖(TVP)及TVP/体表面积(TVP/BSA)。结果显示L4椎体TVP/BSA是预测严重血液学毒性的独立因素,低摄取(<68.7)预示严重毒性风险高(OR 26.0)。

要点

  • L4椎体TVP/BSA是预测铂类双药化疗后严重血液学毒性的独立因素。
  • L4椎体TVP/BSA截断值68.7预测3/4级血液学毒性的敏感度80.0%、特异度86.7%、准确率84.0%。
  • L4椎体TVP/BSA低于68.7时严重血液学毒性风险显著增高(OR 26.0,p=0.000026)。

核心结论

  • 低18F-FLT在低位椎体的摄取是接受铂类双药化疗的肺癌患者发生严重血液学毒性的预测因素。

研究设计与样本

  • 经机构审查委员会批准的回顾性研究,纳入50例原发性肺癌患者,在铂类双药化疗前进行18F-FLT PET扫描,评估Th4、Th8、Th12和L4椎体的标准化摄取值、TVP及TVP/BSA,分析这些参数与化疗期间严重血液学毒性频率的关联。

诊断标准与关键数值

  • L4椎体TVP/BSA截断值68.7预测3/4级血液学毒性的敏感度80.0%、特异度86.7%、准确率84.0%;多因素logistic回归显示L4椎体TVP/BSA(OR 0.94,p=0.0036)和既往临床试验中3/4级血液学毒性频率(OR 1.03,p=0.023)为独立预测因素;L4椎体TVP/BSA低于68.7作为二分类变量是严重血液学毒性的显著指标(OR 26.0,p=0.000026)。

临床应用与阅片要点

  • 原文指出,使用18F-FLT PET成像评估骨髓腔内造血细胞的数量和活性可提供严重血液学毒性的预测数据,并帮助确定晚期恶性疾病患者的适当药物组合或剂量强度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Although hematological toxicities (HT) are the leading adverse events of systemic chemotherapy, the estimation of severe HT is challenging. Recently, 3'-deoxy-3'-[18F]-fluorothymidine (18F-FLT) accumulation with PET has been considered a biomarker of the cell proliferation. This study aims to elucidate whether the vertebral accumulation of 18F-FLT could estimate severe HT during platinum-doublet chemotherapy.

METHODS: In this Institutional Review Board-approved retrospective study, 50 patients with primary lung cancer underwent 18F-FLT PET scan before platinum-doublet chemotherapy. We evaluated the standardized uptake value, total vertebral proliferation (TVP), and TVP/body surface area (TVP/BSA) of the vertebral body (Th4, Th8, Th12, and L4), and then the associations between those parameters and frequency of severe HT during platinum-doublet chemotherapy were assessed.

RESULTS: Severe HT (grade 3/4) was observed in 40.0% of patients during the first cycle. The ROC curve analyses revealed that the TVP/BSA of L4 was the most discriminative parameter among PET parameters for the prediction of severe HT. The multivariate logistic regression analysis revealed the TVP/BSA of L4 (odds ratio [OR], 0.94; p = 0.0036) and the frequency of the grade 3/4 hematological toxicity in previous clinical trials (OR, 1.03; p = 0.023) were independent predictors. Furthermore, the sensitivity, specificity, and accuracy of the TVP/BSA of L4 cut-off of 68.7 to predict grade 3/4 HT were 80.0%, 86.7%, and 84.0%, respectively. A low TVP/BSA of L4 (< 68.7) as a binary variable was a significant indicator of severe HT (OR, 26.0; p = 0.000026).

CONCLUSIONS: The low 18F-FLT uptake in the lower vertebral body is a predictor of severe HT in patients with lung cancer who receive platinum-doublet chemotherapy.

TRIAL REGISTRATION: Trial registration: UMIN000027540 KEY POINTS: • The vertebral 18 F-FLT uptake with PET is an independent predictor of the severe hematological toxicity during the first cycle of platinum-doublet chemotherapy. • The 18 F-FLT uptake in L4 vertebral body estimated hematological toxicities better than that in the upper vertebra (Th4, Th8, and Th12). • The evaluation of the amount and activity of hematopoietic cells in the bone marrow cavity using 18 F-FLT PET imaging could provide predictive data of severe hematological toxicities and help determine an appropriate drug combination or dose intensity in patients with advanced malignant diseases.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Umeda Y, Tsujikawa T, Anzai M, et al. The vertebral 3'-deoxy-3'-18F-fluorothymidine uptake predicts the hematological toxicity after systemic chemotherapy in patients with lung cancer. Eur Radiol. 2019. PMID: 30972546. doi:10.1007/s00330-019-06161-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。